Transregional Collaborative Research Centre 152
print


Breadcrumb Navigation


Content

Alessandra Moretti

Ale photo

CURRENT POSITION / JOB:

Group leader, Molecular and Cellular Cardiology
First Department of Medicine
Klinikum rechts der Isar, Technical University of Munich
Ismaninger Str.22, Munich 81675, Germany
Phone: +49-(0)89-4140-6907, Fax: +49-(0)89-4140-4901

CURRENTLY LIVES IN: Munich

HOME TOWN / COUNTRY: Italy

FORMER POSITIONS / TRAINING / STUDIES:

Academic Education
1992 Diploma in Chemistry and Pharmaceutical Sciences (summa cum laude),
Dept. of Pharmacology, University of Padua, Padua, Italy

Advanced Professional Degrees
1997 PhD in Pharmacology and Toxicology (excellent), Dept. of Biomedical and Experimental Sciences
University of Padua, Padua, Italy

Positions held

  • 1997-2002 Postdoc, Cardiology Division, First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany
  • 2002-2005 Project scientist, Institute of Molecular Medicine, University of California San Diego, USA
  • 2005-2008 Instructor in Medicine, Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, USA
  • 2006-present Group leader in molecular and cellular cardiology, Cardiology Division, First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany

Awards and Honors

  • 1992 Research award for young scientists (Bracco Companies)
  • 1993 Boards in Pharmacy
  • 1998 Astra-Zeneca Award for Young Investigators in Cardiovascular Science
  • 2012 Göttingen Academy of Sciences Award for Biology
  • 2013 Innovationspreises der Deutschen Hochschulmedizin e.V.

PREFERRED LANGUAGES: English, Italian, German

CHILDREN: 0

STIPENDS / GRANTS:

  • Federal Ministry of Education and Research (BMBF) grant 01GN0826: Generation of Isl1+ cardiac progenitors from reprogrammed fibroblasts (2008-2011)
  • German Research Foundation (DFG) Programme Grant 923, Project TP10: Modeling LQT2 Syndrome in cardiac myocytes from patient-specific induced pluripotent stem cells (2010-2013)
  • German Centre for Cardiovascular Research (DZHK) Grant: iPSC disease models in cardiovascular medicine (2011-2018)
  • German Research Foundation (DFG) Programme Grant SFB/TRR152, Project TP17: Patient-specific induced pluripotent stem cell models to elucidate the role of TRP channels in the pathogenesis of CPVT1 and of PFHBI (2014-2018)

E-MAIL ADDRESS / HOMEPAGE: amoretti@mytum.de
http://www.med1.mri.tum.de/en/node/169

PUBLICATIONS:

Original publications (peer-reviewed)
Forti L, Tottene A, Moretti A & Pietrobon D (1994). Three novel types of voltage-dependent calcium channels in rat cerebellar neurons. J. Neurosci. 14:5243-5256.

Tottene A, Moretti A & Pietrobon D (1996). Functional diversity of P-type and R-type calcium channels in rat cerebellar neurons. J. Neurosci. 16:6353-6363.

Laugwitz K-L, Ungerer M, Schöneberg T, Weig H-J, Kronsbein K, Moretti A, Hoffmann K, Seyfarth M, Schultz G & Schömig A (1999). Adenoviral gene transfer of the human V2 vasopressin receptor improves contractile force of rat cardiomyocytes. Circulation 99:925-933.

Weig H-J, Laugwitz K-L, Moretti A, Kronsbein K, Städele C, Brüning S, Seyfarth M, Brill T, Schömig A & Ungerer M (2000). Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors in vivo by ultrasound-guided injection or transcoronary delivery. Circulation 101:925-933.

Laugwitz K-L, Weig H-J, Moretti A, Hoffmann E, Übelacker P, Pragst I, Rosport K, Schömig A & Ungerer M (2001). Gene transfer of heterologous G-Protein-coupled receptors to cardiomyocytes: differential effects on contractility. Circ. Res. 88:688-695.

Laugwitz K-L*, Moretti A*, Weig H-J, Gillitzer A, Pinkernell K, Ott T, Pragst I, Städelel C, Seyfarth M, Schömig A & Ungerer M (2001). Blocking caspase-activated apoptosis improves contractility in failing myocardium. Hum. Gene Ther. 12:2051-2063. (* contributed equally)

Moretti A, Weig H-J, Ott T, Seyfarth M, Holthoff H-P, Grewe D, Gillitzer A, Bott-Flügel L, Schömig A, Ungerer M & Laugwitz K-L (2002). Essential myosin light chain as a novel target for caspase-3 in failing myocardium. Proc. Natl. Acad. Sci. USA. 99:11860-5.

Li Z, Laugwitz K-L, Pinkernell K, Pragst I, Baumgartner C, Hoffmann E, Rosport K, Münch G, Moretti A, Humrich J, Lohse MJ & Ungerer M (2003). Effects of two G-binding proteins – N-terminal truncated phosducin and C-terminal -adrenergic receptor kinase (ARKct) – in heart failure. Gen. Ther. 10:1354-1361.

Laugwitz K-L*, Moretti A*, Lam J, Gruber P, Yinhong Chen, Woodard S, Lin L-Z, Cai C-L, Lu M, Reth M, Platoshyn O, Yuan J, Evans S & Chien KR (2005). Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 433:647-653. (* contributed equally)

Bott-Flügel L, Weig H-J, Knödler M, Städele C, Moretti A, Laugwitz K-L & Seyfarth M (2005). Gene transfer of the pancaspase inhibitor p35 reduces myocardial infarct size and improves cardiac function. J. Mol. Med. 83:526-534.

Moretti A, Caron, L, Nakano, A, Lam, JT, Chen, Y, Qyang, Y, Sasaki, M, Yunfu, S, Evans, S, Laugwitz, K-L & Chien KR (2006). Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell 127:1151-1166.

Qyang Y, Martin-Puig S, Chiravuri M, Chen S, Xu H, Bu L, Jiang X, Lin L, Granger A, Moretti A, Caron L, Wu X, Clarke J, Taketo MM, Laugwitz K-L, Moon RT, Gruber P, Evans SM, Ding S & Chien KR (2007). The renewal and differentiation of Isl1+ cardiovascular progenitors are controlled by a Wnt/-catenin pathway. Cell Stem Cell 1:1-15.

Moretti A, Bellin M, Jung CB, Thies T, Takashima Y, Bernshausen A, Schiemann M, Fisher S, Moosmang S, Smith AG, Lam JT & Laugwitz KL (2010). Mouse and human induced pluripotent stem cells as a source for multipotent Isl1+ cardiovascular progenitors. FASEB J. 24:700-711.

Onorati M, Camnasio S, Binetti M, Jung CB, Moretti A & Cattaneo E (2010). Generation of neuropotent self-renewing neuronal stem (NS) cells from muose fobroblast-derived induced pluripotent stem (iPS) cells. Mol. Cell. Neurosci. 43:287-295.

Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flügel L, Dorn T, Gödel A, Höhnke C, Hofmann F, Seyfarth M, Sinnecker D, Schömig A & Laugwitz K-L (2010). Patient-specific induced pluripotent stem cell models for long-QT syndrome. N. Engl. J. Med. 363:1397-409.

Jung CB*, Moretti A*, Schnitzler MM, Iop L, Storch U, Bellin M, Dorn T, Ruppenthal S, Pfeiffer S, Goedel A, Dirschinger RJ, Seyfarth M, Lam JT, Sinnecker D, Gudermann T, Lipp P & Laugwitz K-L (2012). Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol. Med. 3:180-191. (* contributed equally)

Zhang H, Zou B, Yu H, Moretti A, Wang X, Yan W, Babcock JJ, Bellin M, McManus OB, Tomaselli G, Nan F, Laugwitz K-L & Li M (2012). Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel. Proc. Natl. Acad. Sci. USA. 109:11866-11871.

Bellin M*, Casini S, Davis RP, D'Aniello C, Haas J, Ward-van Oostwaard D, Tertoolen LGJ, Jung CB, Elliott DA, Welling A, Laugwitz KL, Moretti A* & Mummery CL (2013). Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J. 32:3161-3175 (* corresponding author)

Stoehr A, Neuber C, Baldauf C, Vollert I, Friedrich FW, Flenner F, Carrier L, Eder A, Schaaf S, Hirt MN, Aksehirlioglu B, Tong CW, Moretti A, Eschenhagen T & Hansen A (2014). Automated analysis of contractile force and Ca2+ transients in engineered heart tissue. Am. J. Physio.l Heart Circ. Physiol. 306:H1353-63.

Lahm H*, Doppler S*, Dreßen M, Werner A, Adamczyk K, Schrambke D, Brade T, Laugwitz K-L, Deutsch M-A, Schiemann M, Lange R, Moretti A*, Krane M* (2015). Live fluorescent RNA-based detection of pluripotency gene expression in embryonic and induced pluripotent cells of different species. Stem Cells, 33:392-402 (* contributed equally)

Dorn T, Goedel A, Lam JT, Haas J, Tian Q, Herrmann F, Bundschu K, Dobreva G, Schiemann M, Dirschinger R, Guo Y, Kühl SJ, Sinnecker D, Lipp P, Laugwitz KL, Kühl M, Moretti A (2014). Direct Nkx2-5 transcriptional repression of Isl1 controls cardiomyocyte subtype identity. Stem cells, 2014 Dec 19 [Epub ahead of print].

Orban M, Goedel A, Haas J, Sandrock K, Gärtner F, Jung BC, Zieger B, Kurnik K, Sinnecker D, Wanner G, Laugwitz K-L, Massberg S, Moretti A (2015). Functional comparison of induced pluripotent stem cell- and blood-derived GPIIbIIIa deficient platelets. PlosOne, 10(1):e0115978.

Gramlich M, Pane LS, Zhou Q, Chen Z, Murgia M, Schötterl S, Goedel A, Metzger K, Brade T, Parrotta E, Schaller M, Gerull B, Thierfelder L, Aartsma-Rus A, Labeit S, Atherton JJ, McGaughran J, Harvey RP, Sinnecker D, Mann M, Laugwitz K-L, Gawaz MP, Moretti, A. Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy. EMBO Mol. Med. 2015 (in press)

Editorials

Chien KR, Moretti A & Laugwitz K-L (2004). ES cells to the Rescue. Science 306:239-240.

Evans SM, Moretti A & Laugwitz KL (2010). MicroRNAs in a cardiac loop: progenitor or myocyte? Dev. Cell 19:787-8.

Sinnecker D, Moretti A & Laugwitz KL (2014). Negating the dominant-negative allele: a new treatment paradigm for arrhythmias explored in human induced pluripotent stem cell-derived cardiomyocytes. Eur. Heart J. 35:1019-21.

Sinnecker D, Laugwitz KL, Moretti A (2014). Extending human induced pluripotent stem cell technology to infectious diseases: new model for viral myocarditis. Circ. Res. 115:537-9.

Reviews and Textbooks (peer-reviewed)

Moretti A, Lam J, Evans S, & Laugwitz K-L (2007). Cardiovascular development towards biomedical applicability: Biology of Isl1+ cardiac progenitor cells in development and disease. Cell. Mol. Life Sci. 64:674-682.

Laugwitz K-L, Moretti A, Nakano A & Chien KR (2008). Islet-1 Cardiovascular Progenitors: A single source for heart lineages? Development 135:193-205.

Lam JT, Moretti A & Laugwitz KL (2009). Multipotent progenitor cells in regenerative cardiovascular medicine. Pediatr. Cardiol. 30:690-8.

Lam JT, Moretti A & Laugwitz K-L (2010). Multipotent Progenitor Cells in Regenerative Medicine. In: Heart Regeneration: Stem Cells and Beyond. Editors F. Engel, T. Braun and A.F. Moorman. World Scientific Publishing Co. Pte. Ltd., Singapore.

Sinnecker D, Dirschinger RJ, Goedel A, Moretti A, Lipp P & Laugwitz K-L (2012). Induced pluripotent stem cells in cardiovascular research. Rev Physiol Biochem Pharmacol. 163:1-26.

Dirschinger RJ, Goedel A, Moretti A, Laugwitz K-L & Sinnecker D (2012). Recapitulating Long-QT Syndrome Using Induced Pluripotent Stem Cell Technology. Pediatr. Cardiol. 33:950-958.

Sinnecker D, Goedel A, Dorn T, Dirschinger RJ, Moretti A & Laugwitz K-L (2013). Modeling Long-QT Syndromes with iPS Cells. J. Cardiovasc. Transl. Res. 6:31-6.

Sinnecker D, Goedel A, Laugwitz K-L & Moretti A (2013). Induced pluripotent stem cell-derived cardiomyocytes: a versatile tool for arrhythmia research. Circ. Res. 112:961-8.

Brade T, Pane SL, Moretti A, Chien KR & Laugwitz KL (2013). Embryonic Heart Progenitors and Cardiogenesis. In: The biology of Heart Disease. Editors Buckingham M, Mummery CL, and Chien KR. Cold Spring Harb Perspect Med 3;3:a013847

Moretti A, Laugwitz KL, Dorn T, Sinnecker D & Mummery C (2013). Pluripotent Stem Cell Models of Human Heart Disease. In: The biology of Heart Disease. Editors Buckingham M, Mummery CL, and Chien KR. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014027

Sinnecker D, Laugwitz KL & Moretti A (2014). Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testing. Pharmacol. Ther. 143:246-52.